Conclusion: Newer Anticoagulants

[Guest guest]

Dear Members, First of all I am extremely thankful to Dr. Vijay Thawani Sir for giving me an opportunity to

moderate this E-discussion on 'Newer anticoagulants' on the NetRUM. To conclude, although the newer anticoagulants specially the oral ones (Ximelagatran, Dabigatran, Rivaroxaban, Apixaban) are recently introduced and under/ just cleared phase III clinical trials; due to their favorable efficacy & safety profiles, it appears that these medicines are poised to challenge warfarin's dominance in the prevention and therapy of thrombotic disease. Regards,Dr. Vijaya Chaudhari.JR-3,Dept. of Pharmacology,Government Medical College, Nagpur.